Estimated risk of transmission of the West Nile virus
through blood transfusion in the US, 2002 by Biggerstaff, Brad J. & Petersen, Lyle R.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Public Health Resources Public Health Resources 
2003 
Estimated risk of transmission of the West Nile virus through 
blood transfusion in the US, 2002 
Brad J. Biggerstaff 
Centers for Disease Control and Prevention, bbiggerstaff@cdc.gov 
Lyle R. Petersen 
Centers for Disease Control and Prevention, lpetersen@cdc.gov 
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources 
 Part of the Public Health Commons 
Biggerstaff, Brad J. and Petersen, Lyle R., "Estimated risk of transmission of the West Nile virus through 
blood transfusion in the US, 2002" (2003). Public Health Resources. 235. 
https://digitalcommons.unl.edu/publichealthresources/235 
This Article is brought to you for free and open access by the Public Health Resources at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by 
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
T R A N S F U S I O N  C O M P L I C A T I O N S
Estimated risk of transmission of the West Nile virus
through blood transfusion in the US, 2002
Brad J. Biggerstaff and Lyle R. Petersen
Volume 43, August 2003 TRANSFUSION 1007
ABBREVIATION: WNV = West Nile virus.
From the Division of Vector-Borne Infectious Diseases, National
Center for Infectious Diseases, Centers for Disease Control and
Prevention, Fort Collins, Colorado.
Address reprint requests to: Brad Biggerstaff, PhD, Division
of Vector-Borne Infectious Diseases, Centers for Disease Control
and Prevention, PO Box 2087, Fort Collins, CO 80522-2087; 
e-mail: bbiggerstaff@cdc.gov.
Received for publication January 29, 2003; revision
received March 13, 2003, and accepted April 17, 2003.
TRANSFUSION 2003;43:1007-1017.
BACKGROUND: The West Nile virus (WNV) epidemic
in 2002 in the US saw over 3300 reported human
cases of WNV disease, with over 2300 reported cases
of WNV encephalitis and meningitis. The first docu-
mented cases of transfusion transmission of WNV
through voluntary blood donation also occurred.
STUDY DESIGN AND METHODS: Case onset dates
from the 2002 WNV epidemic in the US were used to
estimate the risk of transfusion-associated transmission
with statistical resampling. An easily computed approxi-
mating formula for the mean risk was derived. Esti-
mates were computed for six high-incidence states and
metropolitan areas.
RESULTS: Mean and maximum risk of transfusion-
associated WNV transmission (per 10,000 donations)
during the epidemic period for the selected states
ranged from 2.12 to 4.76 and from 4.34 to 10.46,
respectively; for the selected metropolitan areas, they
ranged from 1.46 to 12.33 and from 3.02 to 21.32,
respectively.
CONCLUSIONS: Estimates of the mean risk of WNV
transmission by transfusion ranged from 1.46 to 12.33
per 10,000 donations for six high-incidence metropolitan
areas during the 2002 epidemic. Because the risk was
highly geographically and temporally variable, computa-
tion of geographically localized estimates is recom-
mended. The derived approximating formula for the
mean risk performed well for the estimates given.
W
est Nile virus (WNV), a mosquito-borne
flavivirus, was first identified in North
America in an epizootic among birds 
and horses and an epidemic of human
encephalitis and meningitis in the New York City metro-
politan area in the late summer and fall 1999.1 Human
infection can result in a wide array of outcomes, rang-
ing from asymptomatic to a flu-like febrile illness to
encephalitis and meningitis, which may result in death.
Cases of human WNV encephalitis and meningitis and of
other WNV disease have been reported in the US each year
since the initial 1999 outbreak, during which 62 cases were
identified. Over the 4 years following its introduction in
New York, WNV spread south through the Atlantic and
Gulf coastal states, west into the Ohio Valley and midwest,
and on into the Great Plains and Rocky Mountain states.
By 2002, WNV was detected in every state east of the con-
tinental divide, with many reports of avian, equine, and
human illness throughout this region. As of November 30,
2002, more than 3300 cases of WNV-associated human
illness with onset dates in 2002 were reported, with 201
deaths from 37 states and the District of Columbia.2 This
is the largest outbreak of an arboviral disease recorded in
the US and the largest outbreak of WNV meningoen-
cephalitis ever recorded.2,3
We previously estimated the risk of transfusion-
associated WNV transmission from donations collected
during the 1999 WNV outbreak in Queens, New York, with
case onset data from the outbreak and historic data on
WNV viremia timing and duration in humans.4 With sta-
tistical resampling methods, the mean risk (per 10,000
donations) of transfusion-associated transmission was
estimated for Queens in 1999 as 1.8 (95% CI, 1.4-2.2) from
donations collected over the course of the outbreak, and
the maximum risk (per 10,000 donations) was estimated
as 2.7 (95% CI, 0.9-5.6).4
Subsequentially during the 2002 WNV epidemic,
WNV transmission through transplanted organs and
blood donation was documented.5 Documentation of
transfusion-related WNV transmission has raised the
question of screening the US blood supply for WNV; quan-
titative assessment of the risk of transfusion-associated
WNV transmission will help determine the potential ben-
efit of this approach. The risk of transfusion-associated
transmission of WNV throughout the 2002 epidemic in 
the US is estimated, and a simple formula to estimate 
the mean risk during the outbreak given. Because 
mosquito-borne WNV transmission is highly localized 
geographically, so that WNV transfusion-associated trans-
fusion risk can vary geographically, we provide estimates
for the six states with the highest incidence of reported
WNV meningoencephalitis (meningitis, encephalitis, or
both) and for six high-incidence metropolitan areas. A
map of county-level incidences of WNV meningoen-
cephalitis in the 48 contiguous US states and the District
of Columbia is shown in Fig. 1. Table 1 lists the states and
metropolitan areas for which estimates were computed
along with summary statistics of the 2002 outbreak in
these areas.
MATERIALS AND METHODS
General approach
We estimated the risk of transfusion-associated WNV
transmission from reported cases of WNV meningoen-
cephalitis with their dates of symptom onset during the
2002 epidemic along with historic data on the timing and
duration of viremia in humans.6 Statistical resampling of
these data was used to estimate at any time t during the
outbreak the number of persons in the population of
interest who were viremic and asymptomatic, although
for persons who developed symptoms, only the time of
viremia before symptom onset was included. This pro-
vides a curve, indexed by time t, which estimates the
BIGGERSTAFF AND PETERSEN
1008 TRANSFUSION Volume 43, August 2003
Fig. 1. Incidence of reported cases of WNV meningoencephalitis per 100,000 population by county, 2002. Data are as of January 21,
2003, using population data from the 2000 US Census (http://www.census.gov). Incidence per 100,000: () 0; ( ) >0 to 0.09; ( ) 0.1
to 0.9; () 1+.
number of potential donors who may transmit WNV
through donation over time. We then divided this curve by
the population size to estimate the risk of transfusion-
associated WNV transmission. Throughout the remainder
of the article, the term “case” is used to mean a case of
WNV meningoencephalitis.
Study population and data
The populations of interest were the inhabitants of the
regions listed in Table 1 during the 2002 WNV outbreak.
Symptom onset dates were used for the cases of WNV
meningoencephalitis from the 2002 outbreak as reported
by state health departments to and compiled by the Divi-
sion of Vector-Borne Infectious Diseases, National Center
for Infectious Diseases, CDC (Fort Collins, CO). All esti-
mates given are based on reports of WNV meningoen-
cephalitis cases through January 21, 2003.
Figures 2 and 3 show pin plots of the symptom onset
dates of the cases of WNV meningoencephalitis for the
regions listed in Table 1 during 2002 reported to the CDC
through January 21, 2003. Illinois and Michigan reported
the largest numbers of cases, with the corresponding
largest numbers of cases from the metropolitan areas of
Chicago and Detroit. Apparent in these graphs is that the
outbreak started earlier and lasted longer in the southern
states (Louisiana and Mississippi).
Historic data on WNV viremia distribution
We supplemented the observed case symptom onset data
with historic data from which an assumed distribution for
the duration from viremia initiation to symptom onset is
derived and from an experimental study by Southam and
Moore6 on the duration of WNV viremia.
The time from WNV inoculation to symptom onset,
the incubation period, is not precisely known but has
been reported to be approximately 2 to 6 days.7-9 Because
there is roughly a 1- to 2-day lag between inoculation with
WNV and its detection in the blood, it is assumed that the
duration from initiation of viremia to symptom onset is
approximately 1 to 5 days.7
In a study of human WNV infection, Southam and
Moore6 give data in their Fig. 4 on the duration of viremia
in cancer patients experimentally infected with WNV. The
patients were stratified by severity of WNV-associated
illness, and those data from patients with demonstrable
viremia who displayed either no or mild symptoms were
used, because these persons are most representative of
WNV-infected persons unlikely to self-defer from dona-
tion. These 50 patients had mean viremia duration of 6.3
days with a SD of 2.7 days and median viremia duration
of 6.5 days with a range of 1 to 11 days.
Statistical analysis
As detailed below, a statistical resampling approach was
used to estimate for any time t during the outbreak the
number of infected persons in the population of interest
who were viremic and asymptomatic, excluding the time
after symptom onset for persons who developed symp-
toms, and we then divided this estimate by the population
size to yield an estimate of the risk of transfusion-
associated WNV transmission at time t. This computation
differs slightly from the method used for the Queens 1999
outbreak4 in that we now account both for infected and for
viremic persons who remain asymptomatic and for
persons who are asymptomatic at time t but who later
develop symptoms.
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TABLE 1. Regions for which WNV transfusion risk estimates are computed, with summary WNV case 
counts and incidence*
Region First case Last case Outbreak length (days) Number of cases Population Incidence (per 100,000)
State
Illinois July 10 October 13 95 524 12,419,293 4.22
Louisiana June 10 November 22 165 205 4,468,976 4.59
Michigan July 20 October 25 97 500 9,938,444 5.03
Mississippi June 24 December 14 173 157 2,844,658 5.52
Nebraska August 4 September 30 57 65 1,711,263 3.80
Ohio July 27 October 13 78 296 754,844 2.61
Metropolitan area†
Chicago, IL July 10 October 1 83 409 6,096,533 6.71
Cleveland, OH July 30 October 3 65 146 1,363,264 10.71
Detroit, MI July 29 October 25 88 414 4,080,742 10.15
Houston, TX July 4 November 24 143 95 3,400,578 2.79
Memphis, TN July 30 September 19 51 33 826,330 3.99
St. Louis, MO/IL July 14 October 10 88 92 1,841,507 5.00
* Number of WNV cases and incidence is of meningoencephalitis only. Population is from the 2000 US. Census (http://www.census.gov).
† Metropolitan area as defined by counties: Chicago (Cook and Du Page); Cleveland (Cuyahoga); Detroit (Wayne, Oakland, Macomb);
Houston (Harris); Memphis (Shelby); St. Louis (St. Louis, St. Louis City, MO; Madison, St. Clair, IL).
One-thousand replications of the simulated risk
curve, indexed by time t, were averaged to produce a final
risk curve estimate. Each replication was computed by
viewing the case symptom onset times as anchor times
and then simulating viremia times for each case based on
the exogenous information on viremia timing and dura-
tion. Because the underlying WNV infection process is
continuous, but the case onset data are recorded as dis-
crete (in days), the first step in the estimation procedure
was to smooth the case onset times by adding an inde-
pendent smoothing component. To simulate a viremia
time for a case, we sampled from an assumed distribution4
for the duration from onset of viremia to symptom onset
and then subtracted this duration from the smoothed case
onset time to represent the time of viremia onset for the
case. We next sampled a viremia duration from the
Southam and Moore6 data and added this to the simulated
viremia onset time; the resulting time represented the end
of the viremia duration for the case. This procedure was
repeated for each case. At this point, then, we have for
each case a simulated viremia time or duration, expressed
as start and end times of viremia.
It was estimated in the WNV seroepidemiologic
survey conducted during the 1999 Queens outbreak that
for each case of WNV meningoencephalitis there are 140
WNV-infected persons in the population.10 In our compu-
tations, therefore, each case’s simulated viremia time rep-
resents 140 persons’ viremia times in the population, and
each of the case’s simulated viremia times was thus repli-
cated 140 times. It was further estimated in the same study
that 21 percent of people infected with WNV develop at
least one symptom as a result of the WNV infection, while
79 percent of the WNV-infected people remain asymp-
tomatic.Therefore, in our computations, a random sample
of 21 percent of the replicated, simulated viremia times
represent symptomatic persons; included for these are
only the time before they developed symptoms (and so
were potential donors) by truncating these randomly
sampled simulated viremia times at the time of symptom
onset. For each time t during the outbreak, the number of
the resulting simulated durations that contain t were
computed to find the estimate for that replication of the
number of asymptomatic, viremic persons in the popula-
tion at time t.
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Fig. 2. Number of persons with WNV meningoencephalitis in high-incidence states, reported as of January 21, 2003, by symptom
onset date. Note that the individual panels use different scales for the vertical axes.
Finally, we averaged all of the 1000 replicated viremia
curves and divided by the population size to yield an esti-
mated risk curve, which is a curve indexed by time t that
represents the risk of transfusion-associated WNV trans-
mission over the course of the outbreak. Simultaneous
confidence bands for the true number of cases viremic at
any given time during the outbreak are computed based
on this computation with the percentile-t approach of
Cowling et al.4,11 The mean and maximum risks (and asso-
ciated CIs) over the course of the outbreak provide conve-
nient summaries of the full risk curve, so these are also
computed. A detailed mathematical development of this
approach can be found in Biggerstaff and Petersen,4
although slight modifications to that development would
be needed to account for the minor adjustments made
here.
When inferring to “the population,” which varies here
as defined by the regions given in Table 1, the following
assumptions are made. First, the dates of infection of the
cases with known symptom onset dates are similar to
those of all residents of the area of interest who became
infected. Next, it is assumed that the ratio of the number
of WNV meningoencephalitis cases to the number of
asymptomatic infections is constant across time, as is the
size of the population at risk. Finally, it is assumed that the
rate of blood donation is constant over the area and time
of interest and that potential blood donors have the same
risk of infection with WNV as the general population of the
area of interest.
Because of the method used to compute the mean
risk of transfusion-associated WNV transmission, it is
expected that incidence, I, of WNV meningoencephalitis
cases and the mean risk of transfusion transmission are
closely related. For each WNV meningoencephalitis case,
we assumed 140 infected persons in the population, 79
percent of whom are expected not to develop symptoms
from the infection. Each of these persons is on average
viremic for 6.3 days, and each of the persons who develop
symptoms is viremic a mean of 3 days before developing
symptoms. Combining this with the length of the out-
break, L, gives the proportion of time an individual is
viremic during the outbreak; that is, it provides an esti-
mate of the probability that that person donates blood
while viremic. We therefore have the following simple
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Fig. 3. Number of persons with WNV meningoencephalitis in high-incidence metropolitan areas, reported as of January 21, 2003, by
symptom onset date. Note that the individual panels use different scales for the vertical axes.
formula for mean risk (per 10,000 donations) based on I
and L, where a scaling factor of 0.1 is included because I
is reported per 100,000, while the mean risk of transfusion
transmission is reported per 10,000:
(1)
CIs for the mean risk based on this approximation may be
computed with standard CIs for the incidence and multi-
plying the result by 78/L.
All computations were performed with computer
software (S-Plus 6.1 Professional for Windows, Insightful
Corp., Seattle, WA) with existing routines or routines
written by the authors. (The use of S-Plus is not to be con-
strued as an endorsement of the product by the authors.)
RESULTS
For the states listed in Table 1, the estimated maximum
risk of transfusion-associated WNV transmission ranged
Average Risk ª
¥ ¥ + ¥ ¥
¥ ¥
ª ¥
140 0 79 6 3 140 0 21 3
0 1
78
. . .
.
.
L
I
L
I
from 4.34 to 10.46 per 10,000 donations (Fig. 4), while the
mean risks ranged from 2.12 to 4.76 per 10,000 donations.
Maximum risk estimates ranged from 3.02 to 21.32 per
10,000 donations for the metropolitan areas listed in Table
1 (Fig. 5), while mean risk estimates for these areas ranged
from 1.46 to 12.33 per 10,000 donations. The summary
estimates and associated CIs for each area are reported in
Table 2.
The plots in Figs. 4 and 5 of the estimated risk curves
for the states and metropolitan areas provide detailed
information for each location. As expected, the curves
follow the general trends of the case reporting data shown
in Figs. 2 and 3. Also as anticipated, fewer reported cases
result in greater uncertainty, evidenced in Figs. 6 and 7 by
the wider confidence bands for the states and metropoli-
tan areas reporting fewer cases.
To facilitate direct comparison among the state and
the metropolitan area estimates, just the estimated risk
curves themselves are plotted, without confidence bands,
in graphs shown in Figs. 6 and 7. In Fig. 6 it can be seen
that Louisiana’s estimated risk curve is long but relatively
low, while Michigan’s is short and noticeably peaked.
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Fig. 4. The estimated transfusion-associated WNV transfusion risk curve (solid, dark line) for the states given in Table 1. Estimates
are from 1000 simulations. Simultaneous 95th percentile-t confidence bands are shown as dashed lines.
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TABLE 2. Summary estimates of WNV transfusion risk based on the estimated risk curve and the approximation to
the mean risk given in Eq. (1)*
Region Average risk 95% CI Maximum risk 95% CI Approximate average risk 95% CI
State
Illinois 3.44 3.32-3.56 8.41 6.78-10.61 3.46 3.18-3.77
Louisiana 2.12 1.99-2.25 4.86 2.98-7.88 2.17 1.89-2.49
Michigan 4.03 3.89-4.17 10.46 8.48-13.20 4.05 3.71-4.42
Mississippi 2.41 2.25-2.58 6.56 3.84-10.85 2.49 2.13-2.91
Nebraska 4.76 4.17-5.36 8.51 4.35-15.66 5.20 4.08-6.62
Ohio 2.54 2.41-2.66 4.34 3.14-6.08 2.61 2.33-2.92
Metropolitan area†
Chicago, IL 6.18 5.94-6.42 14.00 11.03-17.98 6.30 5.72-6.95
Cleveland, OH 12.33 11.38-13.28 20.77 13.28-32.44 12.85 10.93-15.11
Detroit, MI 8.89 8.53-9.25 21.32 16.84-27.45 8.99 8.17-9.90
Houston, TX 1.46 1.33-1.59 3.02 1.37-5.37 1.52 1.25-1.86
Memphis, TN 5.47 4.37-6.57 9.23 3.18-19.02 6.11 4.35-8.58
St. Louis, MO/IL 4.33 3.95-4.70 9.40 5.23-15.87 4.43 3.61-5.43
* Estimates are reported per 10,000 donated units. Outbreak durations vary by location and are reported in Table 1.
† Metropolitan area as defined by counties: Chicago (Cook and Du Page); Cleveland (Cuyahoga); Detroit (Wayne, Oakland, Macomb);
Houston (Harris); Memphis (Shelby); St. Louis (St. Louis, St. Louis City, MO; Madison, St. Clair, IL).
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Fig. 5. The estimated transfusion-associated WNV transfusion risk curves (solid, dark lines) for the metropolitan areas given in
Table 1. Estimates are from 1000 simulations. Simultaneous 95th percentile-t confidence bands are shown as dashed lines.
Cleveland and Detroit have nearly identical estimated risk
curves (Fig. 7).
We can verify this relationship between the mean risk
as computed with the resampling and the full risk curve
and the approximating formula given in Eq. (1) for the
data set at hand by plotting, as in Fig. 8, (78/L) ¥ I against
the estimated mean risk for each region reported in Table
2. The approximating values computed with Eq. (1) are
listed in Table 2. If the approximation is good, the points
should follow a straight line with slope 1. As seen in 
the graph, the points do appear to lie near the equality
line, although two points, representing Memphis and
Nebraska, have slightly higher approximating values for
the mean risk than computed from the estimated risk
curve. Nevertheless, the easily computed formula in Eq.
(1) appears to be a reasonable approximation to the mean
risk of transfusion over the course of an outbreak. CIs for
the approximate mean risks are also reported in Table 2,
where the score CI has been used. These approximating
CIs are wider than those computed with the resampling
method from the estimation of the risk curve.
DISCUSSION
The WNV epidemic varied considerably geographically,
and the corresponding estimated transfusion-associated
WNV transfusion risk from units collected in any particu-
lar area also varied. Among the analyzed metropolitan
areas, the mean risk was as high as 12.33 per 10,000 dona-
tions in Cleveland, with a maximum risk of as high as
21.32 per 10,000 donations in Detroit. These risks are high
compared to the estimated risks for other blood-borne
pathogens in the US blood supply. In particular, the esti-
mates of mean risk given are nearly 2000 times as high as
than those reported for the regularly screened pathogens
HCV and HIV, and they are some 200 times as high as that
for HBV.12 Compared to these other pathogens, however,
the risk for transfusion-associated transmission of WNV is
highly temporally and spatially limited. Furthermore, the
estimates given are during a large epidemic, during which
natural transmission of the virus is highest.
WNV transmission from infected RBCs, PLTs, and FFP
has been documented and development5 of NATs suitable
for WNV screening of the US blood supply is now under
way (http://www.fda.gov/cber/safety/westnile.htm). The
cost-effectiveness of WNV nucleic acid screening will
largely depend on the incidence of WNV infection among
potential blood donors. Compared to other pathogens
screened in the US blood supply, WNV has a very short
duration in blood and its incidence in the US to date is
highly variable, both geographically and temporally. The
cost-effectiveness of screening is therefore likely to vary
BIGGERSTAFF AND PETERSEN
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Fig. 6. Estimated transfusion-associated WNV transfusion risk curves for each state in Table 1. ( ) Illinois; ( ) Louisiana;
(- - -) Michigan; ( ) Mississippi; (·-·-·-) Nebraska; (-···-···) Ohio.
identified donors associated with transfusion-related
WNV transmission to recipients, 3 had symptom onset 
in the days before donation, 5 had symptom onset in the
days after donation, 1 had symptom onset the day of
donation, and 5 remained asymptomatic (CDC, unpub-
lished data). These data suggest that symptomatic persons
may be more likely to transmit WNV infection to blood
recipients, perhaps because they have a higher or longer
viremia than asymptomatic persons. There is insufficient
quantitative or even qualitative information concerning
viremia and symptomatality to make reasonable accom-
modation for it in our method. If asymptomatic but
viremic donors were less likely to transmit WNV, our esti-
mates would be biased high.
An interesting aspect of the 14 identified, WNV-
infected and viremic donors is that 3 of them developed
symptoms before donation. It was assumed in our method
that these persons would have been excluded from dona-
tion. The proportion of symptomatic and viremic persons
from whom donations may for whatever reason be
accepted is unknown, so we are unable to account for this
in our approach. The effect of this would be to bias our esti-
mates downward, as increasing the number of viremic
donors by accepting donations from symptomatic persons
would increase the risk of transfusion-associated WNV
TRANSFUSION RISK OF WEST NILE VIRUS, 2002
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Fig. 7. Estimated transfusion-associated WNV transfusion risk curves for each metropolitan area in Table 1. ( ) Chicago; ( )
Cleveland; ( ) Detroit; (- - -) Houston; (·-·-·-) Memphis; (-···-···) St. Louis.
greatly by year, season, and location; thus, its overall
benefit cannot be fully determined for years to come.
Our data have several limitations, and potential,
unaccounted-for biases may impact our results. The risk
estimates given may overestimate the true transfusion-
associated WNV transmission risk for several reasons. One
is that the proportion of potential viremic blood donors
who would self-defer or be excluded because of symptoms
is unknown. As our estimates incorporate, most infected
persons remain asymptomatic, however, and many symp-
tomatic donors would have symptom onset after dona-
tion, thus limiting the potential impact of symptom-based
self-deferral or exclusion. One-hundred percent transmis-
sion of virus from viremic donors is assumed, and the 
true value is probably less. Our estimates can easily be
adjusted to account for this by multiplying them by the
presumed rate of such transmission. Uncertainties about
the duration of viremia persist, given that the data used
for the duration of viremia were from experimental infec-
tions of cancer patients. The duration of WNV viremia in
cancer patients may, for example, be longer than for pre-
viously healthy persons.
Little is known about the comparative levels of
viremia among asymptomatic persons infected with WNV
and among those who develop symptoms. Of the first 14
transmission. Further, our estimates may be too low if case
ascertainment by the surveillance system is imperfect.
We computed estimates for regions of the US of dra-
matically different geographic size, and the appropriate-
ness of the assumptions underpinning the estimates must
be taken into consideration when interpreting them.
Because the risk of WNV infection is highly localized geo-
graphically, it is expected that the prevalence of viremia
among potential blood donors will vary greatly over the
whole 48 contiguous US states or even over a whole state.
Risk estimates can and should therefore be computed for
smaller geographic areas for which the constant risk
assumption is believed to be more tenable. In our presen-
tation, for example, estimates were provided for the states
of Illinois and Michigan, but the estimates for Chicago and
Detroit, the metropolitan areas with the highest number
of cases in these states, are expected to provide more
accurate estimates of local risk for these areas than pro-
vided by the statewide estimates.
The approximating formula in Eq. (1) for the mean
risk may be most useful for estimating mean transfusion-
associated WNV transmission risk when there are too few
cases for the computation of the estimated risk curve to
be reliable. As an example, the number of reported WNV
meningoencephalitis cases for the Baltimore, Maryland,
metropolitan area (Baltimore, Baltimore City, and Anne
Arundel counties) was nine, spanning over 69 days from
July 27 through October 4, 2002. Using the population
value 1,832,567, derived from 2000 US Census data on the
county level, an estimate of the mean risk can be com-
puted as 78 ¥ (9 ¥ 100,000/1,832,567)/69 = 0.56 per 10,000
donations; the associated score CI is 0.29 to 1.06 per
10,000 donations.
While the formula in Eq. (1) should provide a useful
tool to compute the mean risk, there does not appear 
to be such a straightforward relation between incidence
and the maximum risk. No such relationship should be
expected, however, as the maximum risk depends not only
on the number of WNV meningoencephalitis cases but
also on when they accumulate. Greater detail and infor-
mation is thus contained in the estimated risk curves
plotted in Figs. 4 and 5 than in the estimates of mean risk
only. In particular, transfusion-associated WNV transfu-
sion risk can be more than two times as high near the peak
of the outbreak than the mean would indicate (see the
estimates in Table 2), so that the full risk curve should be
utilized when detailed, time-specific estimates of risk are
required. Nevertheless, estimation of the mean risk by
local or regional agencies who may have only summary
incidence and outbreak length information should find
the approximating formula in Eq. (1) useful when esti-
mating the impact of WNV activity in their areas.
Our methods are reasonably straightforward and
computationally inexpensive, relying only on the avail-
ability of case onset dates and execution of computer 
simulation, but they are indirect. A more direct method 
of estimating the prevalence of WNV-infected units, and
so the risk of transfusion-associated WNV transmission,
would be a direct sampling of donated units and subse-
quent testing of them for the presence of WNV. Given the
magnitudes of the prevalence expected based on the
computations given in this article, such a direct method
of estimation would be expected to require a large number
of samples to achieve reasonable precision. Such studies
in areas with substantial WNV epidemics would help
determine the accuracy of estimates obtained from the
calculations presented here. These direct estimates will
likely prove essential in evaluating future screening mea-
sures for WNV.
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